Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) (NCT04448184)
Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Phase III Trial
🩺 Plain-English Summary (8th-Grade Level)
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Who can join: Review the eligibility criteria below.
Location: Tom Baker Cancer Centre — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Tom Baker Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- Eastern Regional Health Authority — St. John's, Newfoundland and Labrador
- Memorial University — St. John's, Newfoundland and Labrador
- Dalhousie University — Halifax, Nova Scotia
- Hamilton Health Sciences - Juravinski Hospital and Cancer Centre — Hamilton, Ontario
- London Health Sciences Centre — London, Ontario
- The Ottawa Hospital — Ottawa, Ontario
- Niagara Health System — St. Catharines, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Hopital Maisonneuve-Rosemont — Montreal, Quebec
- Saskatchewan Cancer Agency — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (613) 737-8899
Email: sorobert@ohri.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Neoplasms
- Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion — Durham, North Carolina
- Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil — Los Angeles, California
- A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms — Greenville, South Carolina
- A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies — Indianapolis, Indiana
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies — Bethesda, Maryland
Explore by condition: All Hematologic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.